What is Phronesis Artificial Intelligence?
Phronesis Artificial Intelligence offers a sophisticated artificial intelligence-enabled software application designed for fully autonomous de novo drug design and screening. Based in Daphne, Alabama, the company's innovative platform aims to accelerate the drug discovery pipeline by automating complex processes, thereby reducing time and costs associated with bringing new therapeutics to market. The company's focus on AI for drug design positions it at the intersection of cutting-edge technology and critical healthcare needs.
How much funding has Phronesis Artificial Intelligence raised?
Phronesis Artificial Intelligence has raised a total of $300K across 1 funding round:
Angel/Seed
$300K
Angel/Seed (2021): $300K, investors not publicly disclosed
What's next for Phronesis Artificial Intelligence?
With its substantial late-stage funding, Phronesis Artificial Intelligence is poised for significant expansion and market penetration. The capital injection is expected to fuel further development of its AI platform, enhance its screening capabilities, and potentially broaden its application across various therapeutic areas. This strategic backing suggests a clear path towards commercialization and scaling operations, positioning Phronesis Artificial Intelligence as a key player in the future of pharmaceutical innovation.
See full Phronesis Artificial Intelligence company page
